AZN
$183.60-5.33 (-2.82%)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
Recent News
Astrazeneca (AZN) Dips More Than Broader Market: What You Should Know
The latest trading day saw Astrazeneca (AZN) settling at $183.6, representing a -2.82% change from its previous close.
Long-only funds are buying non-US stocks, BofA says
Investing.com -- Long-only investors shifted decisively toward non-U.S. equities in February, according to a new note from Bank of America.
AstraZeneca to boost cell therapy capabilities with new China investment
The planned Shanghai facility extends a yearslong push into the field and will support CAR-T therapies AstraZeneca is making for autoimmune disease and cancer.
Daiichi Sankyo Deepens Biologics Push As ENHERTU Faces FDA Decision
Daiichi Sankyo (TSE:4568) entered a research collaboration with Voro Therapeutics to advance next generation antibody drug conjugates. The company also partnered with Leveragen to expand in vivo antibody discovery capabilities in biologics. ENHERTU, developed with AstraZeneca, was accepted for U.S. FDA Priority Review for certain breast cancer patients following phase 3 data and global filings. Daiichi Sankyo, a major Japanese pharmaceutical group, is leaning further into biologics and...
Saphnelo’s CLE Surge Supports AstraZeneca Valuation Gap And Growth Story
AstraZeneca (LSE:AZN) is seeing rapid uptake of Saphnelo in cutaneous lupus erythematosus (CLE) prescribing. Recent physician data indicates Saphnelo is now used more often than GSK’s Benlysta for biologic management of CLE. The shift in prescribing patterns coincides with several pivotal Saphnelo trials moving toward key readouts. For investors following large cap pharma, this puts AstraZeneca’s immunology push in clearer focus. Saphnelo now sits at the center of the company’s presence in...